Corbus Pharmaceuticals Holdings, Inc. Increase (Decrease) in Contract with Customer, Asset
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Increase (Decrease) in Contract with Customer, Asset of -$212.00 thousand for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-06.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerAsset · last filed 2024-08-06
- Corbus Pharmaceuticals Holdings, Inc. increase (decrease) in contract with customer, asset for the quarter ending 2024-06-30 was $804.00, a 97.31% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. increase (decrease) in contract with customer, asset for the quarter ending 2024-03-31 was -$212.80K, a 885.54% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. increase (decrease) in contract with customer, asset for the quarter ending 2023-12-31 was $11.53K, a 48.26% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. increase (decrease) in contract with customer, asset for the quarter ending 2023-09-30 was -$11.07K, a 107.67% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. increase (decrease) in contract with customer, asset for fiscal 2023 was $57.46K, a 47.27% decline from fiscal 2022.
- Corbus Pharmaceuticals Holdings, Inc. increase (decrease) in contract with customer, asset for fiscal 2022 was $108.96K.
- Corbus Pharmaceuticals Holdings, Inc. increase (decrease) in contract with customer, asset for fiscal 2021 was -$1.62M.
- Corbus Pharmaceuticals Holdings, Inc. increase (decrease) in contract with customer, asset for fiscal 2020 was -$1.06M, a 139.64% decline from fiscal 2019.
| Period end | Increase (Decrease) in Contract with Customer, Asset 3 month | Increase (Decrease) in Contract with Customer, Asset 3 month as first filed | Increase (Decrease) in Contract with Customer, Asset 6 month | Increase (Decrease) in Contract with Customer, Asset 6 month as first filed | Increase (Decrease) in Contract with Customer, Asset 9 month | Increase (Decrease) in Contract with Customer, Asset 12 month | Increase (Decrease) in Contract with Customer, Asset 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2024-06-30 | $804.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$212.00K 10-Q · filed 2024-08-06 | -$200.47K derived: sum of 3 quarters · filed 2024-08-06 | -$211.54K derived: sum of 4 quarters · filed 2024-08-06 | |||
| 2024-03-31 | -$212.80K 10-Q · filed 2024-05-07 | -$201.27K derived: sum of 2 quarters · filed 2024-05-07 | -$212.35K derived: sum of 3 quarters · filed 2024-05-07 | -$182.44K derived: sum of 4 quarters · filed 2024-08-06 | |||
| 2023-12-31 | $11.53K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $458.00 derived: sum of 2 quarters · filed 2024-03-12 | $30.37K derived: sum of 3 quarters · filed 2024-08-06 | $57.46K 10-K · filed 2024-03-12 | |||
| 2023-09-30 | -$11.07K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $18.84K derived: sum of 2 quarters · filed 2024-08-06 | $45.92K 10-Q · filed 2023-11-07 | $68.22K derived: sum of 4 quarters · filed 2024-08-06 | |||
| 2023-06-30 | $29.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $57.00K 10-Q · filed 2024-08-06 | $56.60K 10-Q · filed 2023-08-08 | $79.29K derived: sum of 3 quarters · filed 2024-08-06 | $223.74K derived: sum of 4 quarters · filed 2024-08-06 | ||
| 2023-03-31 | $27.09K 10-Q · filed 2024-05-07 | $49.38K derived: sum of 2 quarters · filed 2024-05-07 | $193.83K derived: sum of 3 quarters · filed 2024-05-07 | ||||
| 2022-12-31 | $22.29K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $166.74K derived: sum of 2 quarters · filed 2024-03-12 | $108.96K 10-K · filed 2024-03-12 | ||||
| 2022-09-30 | $144.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $86.67K 10-Q · filed 2023-11-07 | |||||
| 2022-06-30 | -$57.78K 10-Q · filed 2023-08-08 | ||||||
| 2021-12-31 | -$2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | -$2.40M derived: sum of 2 quarters · filed 2023-03-07 | -$2.27M derived: sum of 3 quarters · filed 2023-03-07 | -$1.62M 10-K · filed 2023-03-07 | |||
| 2021-09-30 | $97.32K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $233.88K derived: sum of 2 quarters · filed 2022-11-08 | $881.70K 10-Q · filed 2022-11-08 | $1.54M derived: sum of 4 quarters · filed 2022-11-08 | |||
| 2021-06-30 | $136.56K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $784.38K 10-Q · filed 2022-08-09 | $1.44M derived: sum of 3 quarters · filed 2022-08-09 | $2.40M derived: sum of 4 quarters · filed 2022-08-09 | |||
| 2021-03-31 | $647.82K 10-Q · filed 2022-05-10 | $1.31M derived: sum of 2 quarters · filed 2022-05-10 | $2.27M derived: sum of 3 quarters · filed 2022-05-10 | -$2.18M derived: sum of 4 quarters · filed 2022-05-10 | |||
| 2020-12-31 | $658.21K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $1.62M derived: sum of 2 quarters · filed 2022-03-08 | -$2.82M derived: sum of 3 quarters · filed 2022-03-08 | -$1.06M 10-K · filed 2022-03-08 | |||
| 2020-09-30 | $960.09K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$3.48M derived: sum of 2 quarters · filed 2021-11-12 | -$1.72M 10-Q · filed 2021-11-12 | $1.07M derived: sum of 4 quarters · filed 2021-11-12 | |||
| 2020-06-30 | -$4.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$2.68M 10-Q · filed 2021-08-12 | $2.68M 10-Q · filed 2020-08-06 | $107.55K derived: sum of 3 quarters · filed 2021-08-12 | |||
| 2020-03-31 | $1.76M 10-Q · filed 2021-05-13 | -$1.76M 10-Q · filed 2020-05-11 | $4.55M derived: sum of 2 quarters · filed 2021-05-13 | ||||
| 2019-12-31 | $2.79M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $2.68M 10-K · filed 2021-03-15 | -$2.68M 10-K · filed 2020-03-16 | ||||
| 2019-09-30 | -$107.55K 10-Q · filed 2020-11-09 | ||||||
| 2019-03-31 | -$423.18K 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |